Conventional and Proteomic Technologies for the Detection of Early Stage Malignancies: Markers for Ovarian Cancer

REFERENCES

• Ariztia E, Lee C J, Gogoi R, Fishman D A. The tumor microenvironment: key to early detection. Crit Rev Clin Lab Sci 2006; 43: 393–425, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ahram M, Adkins J N, Auberry D L, Wunschel D S, Springer D L. A proteomic approach to characterize protein shedding. Proteomics 2005; 5: 123–131, [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Lowenthal M S, Mehta A I, Frogale K, Bandle R W, Araujo R P, Hood B L, Veenstra T D, Conrads T P, Goldsmith P, Fishman D, Petricoin E F, 3rd, Liotta L A. Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 2005; 51: 1933–1945, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kavallaris M, Marshall G M. Proteomics and disease: opportunities and challenges. Med J Aust 2005; 182: 575–579, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Petricoin E F, 3rd, Ornstein D K, Paweletz C P, Ardekani A, Hackett P S, Hitt B A, Velassco A, Trucco C, Wiegand L, Wood K, Simone C B, Levine P J, Linehan W M, Emmert-Buck M R, Steinberg S M, Kohn E C, Liotta L A. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94: 1576–1578, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wulfkuhle J D, Liotta L A, Petricoin E F. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003; 3: 267–275, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Petricoin E F, Liotta L A. Proteomic approaches in cancer risk and response assessment. Trends Mol Med 2004; 10: 59–64, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Petricoin E F, Liotta L A. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004; 15: 24–30, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Plebani M. Proteomics: the next revolution in laboratory medicine?. Clin Chim Acta 2005; 357: 113–122, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Somiari R I, Somiari S, Russell S, Shriver C D. Proteomics of breast carcinoma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 815: 215–225, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dunckley T, Coon K D, Stephan D A. Discovery and development of biomarkers of neurological disease. Drug Discov Today 2005; 10: 326–334, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Diamandis E P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004; 3: 367–378, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Jacobs I J, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3: 355–366, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ozols R F, Rubin S C, Dembo A L, Robboy S J. Epithelial ovarian cancer. Principles and Practice of Gynecologic Oncology, 3rd Ed, W J Hoskins, C A Perez, R C Young. Lippincott Williams and Wilkins, Philadelphia 2000; 981–1058
   Google Scholar
• Zurawski V R, Jr, Orjaseter H, Andersen A, Jellum E. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988; 42: 677–680, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bast R C, Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 2002; 107: 61–97, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Friedlander M L. Prognostic factors in ovarian cancer. Semin Oncol 1998; 25: 305–314, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter J A, Schummer M, McIntosh M, Drescher C, Urban N, Hellstrom K E. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695–3700, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Drapkin R, von Horsten H H, Lin Y, Mok S C, Crum C P, Welch W R, Hecht J L. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162–2169, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mok S C, Chao J, Skates S, Wong K, Yiu G K, Muto M G, Berkowitz R S, Cramer D W. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93: 1458–1464, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mills G B, Bast R C, Jr., Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst 2001; 93: 1437–1439, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Wong K K, Cheng R S, Mok S C. Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system. Biotechniques 2001; 30: 670–675, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kim J H, Skates S J, Uede T, Wong K K, Schorge J O, Feltmate C M, Berkowitz R S, Cramer D W, Mok S C. Osteopontin as a potential diagnostic biomarker for ovarian cancer. Jama 2002; 287: 1671–1679, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yousef G M, Diamandis E P. Expanded human tissue kallikrein family—a novel panel of cancer biomarkers. Tumour Biol 2002; 23: 185–192, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Ghosh M C, Grass L, Soosaipillai A, Sotiropoulou G, Diamandis E P. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol 2004; 25: 193–199, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hassan R, Kreitman R J, Pastan I, Willingham M C. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005; 13: 243–247, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Stanley E R, Guilbert L J, Tushinski R J, Bartelmez S H. CSF-1—a mononuclear phagocyte lineage-specific hemopoietic growth factor. J Cell Biochem 1983; 21: 151–159, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Xu F J, Ramakrishnan S, Daly L, Soper J T, Berchuck A, Clarke-Pearson D, Bast R C, Jr. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol 1991; 165: 1356–1362, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Xu F J, Yu Y H, Li B Y, Moradi M, Elg S, Lane C, Carson L, Ramakrishnan S. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells. Cancer Res 1991; 51: 4012–4019, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Kumanov P, Nandipati K C, Tomova A, Robeva R, Agarwal A. Significance of inhibin in reproductive pathophysiology and current clinical applications. Reprod Biomed Online 2005; 10: 786–812, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Xu Y, Shen Z, Wiper D W, Wu M, Morton R E, Elson P, Kennedy A W, Belinson J, Markman M, Casey G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719–723, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mills G B, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam F H, Wiener J, Lapushin R, Yu S, Parrott J A, Compton T, Tribley W, Fishman D, Stack M S, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson J R. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 2002; 107: 259–283, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Baron A T, Cora E M, Lafky J M, Boardman C H, Buenafe M C, Rademaker A, Liu D, Fishman D A, Podratz K C, Maihle N J. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003; 12: 103–113, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, Asano G. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Gynecol Oncol 1993; 48: 148–154, [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Terry K L, Sluss P M, Skates S J, Mok S C, Ye B, Vitonis A F, Cramer D W. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 2004; 20: 53–70, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky L J, de Bruijn H W, van der Zee A G, Bast R C, Jr, Hacker N F. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001; 92: 2837–2844, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lu K H, Patterson A P, Wang L, Marquez R T, Atkinson E N, Baggerly K A, Ramoth L R, Rosen D G, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson D M, Mills G B, Bast R C, Jr. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004; 10: 3291–3300, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• McIntosh M W, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom K E, Hellstrom I. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol 2004; 95: 9–15, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward D C. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 7677–7682, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Vignali D A. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000; 243: 243–255, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gorelik E, Landsittel D P, Marrangoni A M, Modugno F, Velikokhatnaya L, Winans M T, Bigbee W L, Herberman R B, Lokshin A E. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 981–987, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rosen D G, Wang L, Atkinson J N, Yu Y, Lu K H, Diamandis E P, Hellstrom I, Mok S C, Liu J, Bast R C, Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005; 99: 267–277, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Skates S J, Horick N, Yu Y, Xu F J, Berchuck A, Havrilesky L J, de Bruijn H W, van der Zee A G, Woolas R P, Jacobs I J, Zhang Z, Bast R C, Jr. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004; 22: 4059–4066, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Spentzos D, Levine D A, Ramoni M F, Joseph M, Gu X, Boyd J, Libermann T A, Cannistra S A. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22: 4700–4710, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Spentzos D, Levine D A, Kolia S, Otu H, Boyd J, Libermann T A, Cannistra S A. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 2005; 23: 7911–7918, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken W D, Fellbaum C, Gu X, Joseph M, Pantuck A J, Jonas D, Libermann T A. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005; 11: 5730–5739, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dunbar S A. Applications of Luminex(R) xMAPtrade mark technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta 2006; 363: 71–82, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Johann D J, Jr, McGuigan M D, Patel A R, Tomov S, Ross S, Conrads T P, Veenstra T D, Fishman D A, Whiteley G R, Petricoin E F, 3rd, Liotta L A. Clinical proteomics and biomarker discovery. Ann NY Acad Sci 2004; 1022: 295–305, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Posadas E M, Simpkins F, Liotta L A, MacDonald C, Kohn E C. Proteomic analysis for the early detection and rational treatment of cancer—realistic hope?. Ann Oncol 2005; 16: 16–22, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Chen R, Pan S, Brentnall T A, Aebersold R. Proteomic profiling of pancreatic cancer for biomarker discovery. Mol Cell Proteomics 2005; 4: 523–533, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Emmert-Buck M R, Bonner R F, Smith P D, Chuaqui R F, Zhuang Z, Goldstein S R, Weiss R A, Liotta L A. Laser capture microdissection. Science 1996; 274: 998–1001, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Banks R E, Dunn M J, Forbes M A, Stanley A, Pappin D, Naven T, Gough M, Harnden P, Selby P J. The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis—preliminary findings. Electrophoresis 1999; 20: 689–700, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Craven R A, Totty N, Harnden P, Selby P J, Banks R E. Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol 2002; 160: 815–822, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhou G, Li H, DeCamp D, Chen S, Shu H, Gong Y, Flaig M, Gillespie J W, Hu N, Taylor P R, Emmert-Buck M R, Liotta L A, Petricoin E F, 3rd, Zhao Y. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 2002; 1: 117–124, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Petricoin E F, Ornstein D K, Liotta L A. Clinical proteomics: applications for prostate cancer biomarker discovery and detection. Urol Oncol 2004; 22: 322–328, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Liotta L A, Petricoin E F, 3rd, Ardekani A M, Hitt B A, Levine P J, Fusaro V A, Steinberg S M, Mills G B, Simone C, Fishman D A, Kohn E C. General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol 2003; 88: S25–28, discussion S37–42[INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Celis J E, Gromov P, Cabezon T, Moreira J M, Ambartsumian N, Sandelin K, Rank F, Gromova I. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 2004; 3: 327–344, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mobley J A, Lam Y W, Lau K M, Pais V M, L'Esperance J O, Steadman B, Fuster L M, Blute R D, Taplin M E, Ho S M. Monitoring the serological proteome: the latest modality in prostate cancer detection. J Urol 2004; 172: 331–337, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ornstein D K, Rayford W, Fusaro V A, Conrads T P, Ross S J, Hitt B A, Wiggins W W, Veenstra T D, Liotta L A, Petricoin E F, 3rd. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol 2004; 172: 1302–1305, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Banez L L, Srivastava S, Moul J W. Proteomics in prostate cancer. Curr Opin Urol 2005; 15: 151–156, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Semmes O J, Feng Z, Adam B L, Banez L L, Bigbee W L, Campos D, Cazares L H, Chan D W, Grizzle W E, Izbicka E, Kagan J, Malik G, McLerran D, Moul J W, Partin A, Prasanna P, Rosenzweig J, Sokoll L J, Srivastava S, Thompson I, Welsh M J, White N, Winget M, Yasui Y, Zhang Z, Zhu L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer. I. Assessment of platform reproducibility. Clin Chem 2005; 51: 102–112, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fuller A P, Palmer-Toy D, Erlander M G, Sgroi D C. Laser capture microdissection and advanced molecular analysis of human breast cancer. J Mammary Gland Biol Neoplasia 2003; 8: 335–345, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ramus C, Gonzalez de Peredo A, Dahout C, Gallagher M, Garin J. An optimized strategy for ICAT quantification of membrane proteins. Mol Cell Proteomics 2005; 5: 68–78, [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Ong S E, Foster L J, Mann M. Mass spectrometric-based approaches in quantitative proteomics. Methods 2003; 29: 124–130, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Petricoin E F, Ardekani A M, Hitt B A, Levine P J, Fusaro V A, Steinberg S M, Mills G B, Simone C, Fishman D A, Kohn E C, Liotta L A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359: 572–577, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Grizzle W E, Adam B L, Bigbee W L, Conrads T P, Carroll C, Feng Z, Izbicka E, Jendoubi M, Johnsey D, Kagan J, Leach R J, McCarthy D B, Semmes O J, Srivastava S, Thompson I M, Thornquist M D, Verma M, Zhang Z, Zou Z. Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers 2003; 19: 185–195, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Li J, White N, Zhang Z, Rosenzweig J, Mangold L A, Partin A W, Chan D W. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J Urol 2004; 171: 1782–1787, [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Loboda A, Ackloo S, Chernushevich I V. A high-performance matrix-assisted laser desorption/ionization orthogonal time-of-flight mass spectrometer with collisional cooling. Rapid Commun Mass Spectrom 2003; 17: 2508–2516, [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Ackloo S, Loboda A V. Applications of a matrix-assisted laser desorption/ionization orthogonal time-of-flight mass spectrometer. l Metastable decay and collision-induced dissociation for sequencing peptides. Rapid Commun Mass Spectrom 2005; 19: 1–8, [CROSSREF], [CSA]
   Google Scholar
• Goodacre R, Neal M J, Kell D B, Greenham L W, Noble W C, Harvey R G. Rapid identification using pyrolysis mass spectrometry and artificial neural networks of Propionibacterium acnes isolated from dogs. J Appl Bacteriol 1994; 76: 124–134, [INFOTRIEVE], [CSA]
   Google Scholar
• Holland R D, Wilkes J G, Rafii F, Sutherland J B, Persons C C, Voorhees K J, Lay J O, Jr. Rapid identification of intact whole bacteria based on spectral patterns using matrix-assisted laser desorption/ionization with time-of-flight mass spectrometry. Rapid Commun Mass Spectrom 1996; 10: 1227–1232, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Conrads T P, Fusaro V A, Ross S, Johann D, Rajapakse V, Hitt B A, Steinberg S M, Kohn E C, Fishman D A, Whitely G, Barrett J C, Liotta L A, Petricoin E F, 3rd, Veenstra T D. High-resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 2004; 11: 163–178, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kozak K R, Amneus M W, Pusey S M, Su F, Luong M N, Luong S A, Reddy S T, Farias-Eisner R. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003; 100: 12343–12348, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rai A J, Zhang Z, Rosenzweig J, Shih Ie M, Pham T, Fung E T, Sokoll L J, Chan D W. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 2002; 126: 1518–1526, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Ye B, Cramer D W, Skates S J, Gygi S P, Pratomo V, Fu L, Horick N K, Licklider L J, Schorge J O, Berkowitz R S, Mok S C. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. Clin Cancer Res 2003; 9: 2904–2911, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Howard B A, Wang M Z, Campa M J, Corro C, Fitzgerald M C, Patz E F, Jr. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 2003; 3: 1720–1724, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Moshkovskii S A, Serebryakova M V, Kuteykin-Teplyakov K B, Tikhonova O V, Goufman E I, Zgoda V G, Taranets I N, Makarov O V, Archakov A I. Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005; 5: 3790–3797, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhang Z, Bast R C, Jr, Yu Y, Li J, Sokoll L J, Rai A J, Rosenzweig J M, Cameron B, Wang Y Y, Meng X Y, Berchuck A, Van Haaften-Day C, Hacker N F, de Bruijn H W, van der Zee A G, Jacobs I J, Fung E T, Chan D W. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882–5890, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Yu J K, Zheng S, Tang Y, Li L. An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. J Zhejiang Univ Sci B 2005; 6: 227–231, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Diamandis E P. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004; 96: 353–356, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Adkins J N, Varnum S M, Auberry K J, Moore R J, Angell N H, Smith R D, Springer D L, Pounds J G. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002; 1: 947–955, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Liotta L A, Ferrari M, Petricoin E. Clinical proteomics: written in blood. Nature 2003; 425: 905, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mehta A I, Ross S, Lowenthal M S, Fusaro V, Fishman D A, Petricoin E F, 3rd, Liotta L A. Biomarker amplification by serum carrier protein binding. Dis Markers 2003; 19: 1–10, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tirumalai R S, Chan K C, Prieto D A, Issaq H J, Conrads T P, Veenstra T D. Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2003; 2: 1096–1103, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhou M, Lucas D A, Chan K C, Issaq H J, Petricoin E F, 3rd, Liotta L A, Veenstra T D, Conrads T P. An investigation into the human serum “interactome”. Electrophoresis 2004; 25: 1289–1298, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Xiao Z, Adam B L, Cazares L H, Clements M A, Davis J W, Schellhammer P F, Dalmasso E A, Wright G L, Jr. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 2001; 61: 6029–6033, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Adam B L, Qu Y, Davis J W, Ward M D, Clements M A, Cazares L H, Semmes O J, Schellhammer P F, Yasui Y, Feng Z, Wright G L, Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62: 3609–3614, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Qu Y, Adam B L, Yasui Y, Ward M D, Cazares L H, Schellhammer P F, Feng Z, Semmes O J, Wright G L, Jr. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002; 48: 1835–1843, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lehrer S, Roboz J, Ding H, Zhao S, Diamond E J, Holland J F, Stone N N, Droller M J, Stock R G. Putative protein markers in the sera of men with prostatic neoplasms. BJU Int 2003; 92: 223–225, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Chanin T D, Merrick D T, Franklin W A, Hirsch F R. Recent developments in biomarkers for the early detection of lung cancer: perspectives based on publications 2003 to present. Curr Opin Pulm Med 2004; 10: 242–247, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Granville C A, Dennis P A. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 2005; 32: 169–176, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 2005; 23: 3219–3226, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Yang S Y, Xiao X Y, Zhang W G, Sun X Z, Zhang L J, Zhang W, Zhou B, Chen G A, He D C. Application of serum surface-enhanced laser desorption/ionization proteomic patterns in distinguishing lung cancer patients from healthy people. Chin Med J (Engl) 2005; 118: 1036–1039, [CSA]
   Google Scholar
• Wong Y F, Cheung T H, Lo K W, Wang V W, Chan C S, Ng T B, Chung T K, Mok S C. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 2004; 211: 227–234, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Castagna A, Antonioli P, Astner H, Hamdan M, Righetti S C, Perego P, Zunino F, Righetti P G. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004; 4: 3246–3267, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Terai A, Arai Y, Iwamura H, Kawakita M, Yoshiki T. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci 2004; 95: 955–961, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Vlahou A, Laronga C, Wilson L, Gregory B, Fournier K, McGaughey D, Perry R R, Wright G L, Jr, Semmes O J. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 2003; 4: 203–209, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Luo Y, Zhang J, Liu Y, Shaw A C, Wang X, Wu S, Zeng X, Chen J, Gao Y, Zheng D. Comparative proteome analysis of breast cancer and normal breast. Mol Biotechnol 2005; 29: 233–244, [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Alessandro R, Belluco C, Kohn E C. Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clin Colorectal Cancer 2005; 4: 396–402, [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Chen J, Kahne T, Rocken C, Gotze T, Yu J, Sung J J, Chen M, Hu P, Malfertheiner P, Ebert M P. Proteome analysis of gastric cancer metastasis by two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-mass spectrometry for identification of metastasis-related proteins. J Proteome Res 2004; 3: 1009–1016, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• He Q Y, Chen J, Kung H F, Yuen A P, Chiu J F. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 2004; 4: 271–278, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Vimalachandran D, Costello E. Proteomic technologies and their application to pancreatic cancer. Expert Rev Proteomics 2004; 1: 493–501, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser D F, Sanchez J C. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003; 3: 1486–1494, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Esselmann H, Meyer M, Wollscheid V, Neumann M, Otto M, Maler J M, Ruther E, Kornhuber J, Wiltfang J. The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom 2003; 17: 1291–1296, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Uchida T, Fukawa A, Uchida M, Fujita K, Saito K. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res 2002; 1: 495–499, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Guillaume E, Zimmermann C, Burkhard P R, Hochstrasser D F, Sanchez J C. A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2003; 3: 1495–1499, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ye B, Skates S, Mok S C, Horick N K, Rosenberg H F, Vitonis A, Edwards D, Sluss P, Han W K, Berkowitz R S, Cramer D W. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006; 12: 432–441, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Liotta L A, Petricoin E F. Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest 2006; 116: 26–30, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sheehan K M, Calvert V S, Kay E W, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills G B, Liotta L A, Petricoin E F, 3rd, Wulfkuhle J D. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 2005; 4: 346–355, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Boyce E A, Kohn E C. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. Int J Gynecol Cancer 2005; 15: 266–273, [INFOTRIEVE], [CROSSREF], [CSA]
   Google Scholar
• Espina V, Mehta A I, Winters M E, Calvert V, Wulfkuhle J, Petricoin E F, 3rd, Liotta L A. Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 2003; 3: 2091–2100, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Liotta L, Petricoin E. Molecular profiling of human cancer. Nat Rev Genet 2000; 1: 48–56, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Wulfkuhle J D, McLean K C, Paweletz C P, Sgroi D C, Trock B J, Steeg P S, Petricoin E F, 3rd. New approaches to proteomic analysis of breast cancer. Proteomics 2001; 1: 1205–1215, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Petricoin E F, 3rd, Bichsel V E, Calvert V S, Espina V, Winters M, Young L, Belluco C, Trock B J, Lippman M, Fishman D A, Sgroi D C, Munson P J, Esserman L J, Liotta L A. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol 2005; 23: 3614–3621, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Paweletz C P, Charboneau L, Bichsel V E, Simone N L, Chen T, Gillespie J W, Emmert-Buck M R, Roth M J, Petricoin I E, Liotta L A. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: 1981–1989, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Wulfkuhle J D, Aquino J A, Calvert V S, Fishman D A, Coukos G, Liotta L A, Petricoin E F, 3rd. Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003; 3: 2085–2090, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rai A J, Stemmer P M, Zhang Z, Adam B L, Morgan W T, Caffrey R E, Podust V N, Patel M, Lim L Y, Shipulina N V, Chan D W, Semmes O J, Leung H C. Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization-time of flight (SELDI-TOF) mass spectrometry: multi-institution correlation of spectra and identification of biomarkers. Proteomics 2005; 5: 3467–3474, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Chambers S K, Kacinski B M, Ivins C M, Carcangiu M L. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Clin Cancer Res 1997; 3: 999–1007, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Garbis S, Lubec G, Fountoulakis M. Limitations of current proteomics technologies. J Chromatogr A 2005; 1077: 1–18, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Swatton J E, Prabakaran S, Karp N A, Lilley K S, Bahn S. Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE). Mol Psychiatry 2004; 9: 128–143, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Patton W F. Detection technologies in proteome analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 771: 3–31, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Patton W F, Schulenberg B, Steinberg T H. Two-dimensional gel electrophoresis; better than a poke in the ICAT?. Curr Opin Biotechnol 2002; 13: 321–328, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• McDonald W H, Yates J R, 3rd. Shotgun proteomics and biomarker discovery. Dis Markers 2002; 18: 99–105, [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Washburn M P, Wolters D, Yates J R, 3rd. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 2001; 19: 242–247, [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar